• ImmuneOnco Biopharmaceuticals (Shanghai) disclosed the planned exit of independent director Zhenping Zhu, effective once a successor is elected.
• The board nominated Liou Hsiou-Chi to join as an independent director, subject to shareholder approval at a general meeting.
• Liou is a former Weill Cornell associate professor, ex-biopharma equity analyst, and co-founder and CEO of ImmuneTarget focused on NF-kB inhibitors.
• She has also worked in wealth management at Bank of America Merrill Lynch and is currently a business advisor at Aprinoia Therapeutics.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals (Shanghai) Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260828-12306756), on August 28, 2026, and is solely responsible for the information contained therein.